Drug Profile


Alternative Names: 3G4; Anti-phosphatidylserine monoclonal antibody 3G4; Anti-phospholipid monoclonal antibody 3G4; Anti-PS MAb 3G4; Monoclonal antibody 3G4; Tarvacin

Latest Information Update: 24 Mar 2017

Price : $50

At a glance

  • Originator Peregrine Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
  • Developer Peregrine Pharmaceuticals; University of Arizona; University of Texas Southwestern Medical Center
  • Class Adjuvants; Antineoplastics; Antivirals; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Immunostimulants; Phosphatidylserine receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Non-small cell lung cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Brain cancer
  • Suspended Breast cancer; Hepatocellular carcinoma; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Rectal cancer
  • No development reported Hepatitis C; HIV infections; Viral haemorrhagic fevers
  • Discontinued Influenza virus infections; Prostate cancer

Most Recent Events

  • 08 Mar 2017 Peregrine Pharmaceuticals withdraws a phase II trial prior to enrolment in Breast cancer (Early stage disease, Adjunctive treatment, Neoadjuvant therapy) in USA (NCT02685306)
  • 10 Oct 2016 Top-line efficacy data from the phase III SUNRISE trial in Non-small cell lung cancer presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
  • 06 Sep 2016 Massachusetts General Hospital Cancer Center plans a phase I/II trial for Glioblastoma (Combination therapy; Newly diagnosed disease) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top